Please wait while the formulary information is being retrieved.
GLYDO (LIDOCAINE HCL)
- Local anesthesia for endotracheal intubation
- Local anesthesia for urethral pain
- Urethritis
- Lidocaine Mucous Membrane Jelly In Applicator
- Lidocaine Mucosal Jelly In Applicator
- Glydo Mucosal Jelly In Applicator
lidocaine 2 % mucosal jelly in applicator
- Dosage information is not available
lidocaine 2 % mucosal jelly in applicator
- Dosage information is not available
2 % mucosal jelly in applicator
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Methemoglobinemia
Contraindicated
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart block
- Hemolytic anemia from PK and g6PD deficiencies
- Shock
Severe
Moderate
- None
GLYDO (LIDOCAINE HCL)
- Local anesthesia for endotracheal intubation
- Local anesthesia for urethral pain
- Urethritis
- None
- None
More Frequent
Severe
Less Severe
- Angioedema
- Dermatitis due to topical drug
- Erythema
- Pruritus of skin
- Skin rash
- Stinging of skin
- Urticaria
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Anaphylaxis
- Bradycardia
- Cardiac arrhythmia
- CNS toxicity
- Cyanosis
- Drowsy
- Eyelid edema
- Headache disorder
- Hypotension
- Methemoglobinemia
- Respiratory depression
- Seizure disorder
- Tremor
- Unconsciousness
Less Severe
- Acute confusion
- Apprehension
- Blurred vision
- Dizziness
- Edema
- Euphoria
- Nervousness
- Sensation of cold
- Sensation of warmth
- Tinnitus
- Twitching
- Vomiting
Contraindicated
None
Severe Precaution
Lidocaine (Select routes)
Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
- 180 Days – 16 Years
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
Management or Monitoring Precaution
None
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
Select Anesthetics
General-May be more sensitive to CNS and cardiac adverse reactions. Consider dose reduction due to reduced clearance in the elderly.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Urethritis | |
| N34.1 | Nonspecific urethritis |
| N34.2 | Other urethritis |
| 0-9 | A-Z |
|---|---|
| N34.1 | Nonspecific urethritis |
| N34.2 | Other urethritis |
Formulary Reference Tool